Figure 5 | Scientific Reports

Figure 5

From: A Novel 3D In Vitro Platform for Pre-Clinical Investigations in Drug Testing, Gene Therapy, and Immuno-oncology

Figure 5The alternative text for this image may have been generated using AI.

In VITVO testing of the effect of nivolumab on lung primary tumor. (a) Experimental scheme. (b) Immunostaining of unfractionated tumor cells dissociated from lung cancer specimen with anti-CD3, anti-CD4, and anti-CD8 to quantify the percentage of immune cells (CD3+) and the cell subpopulations of lymphocyte T helper (CD4+) and lymphocyte T cytotoxic (CD8+). (c) In VITVO cell viability evaluation based on RealTime-Glo at seeding and after 24 hours of treatment with nivolumab. Real Time GLO was used at a 1X final concentration for both measurements. Untreated samples were used as control. All measurements were performed in triplicate and data are expressed as means ± SD, *P = 0.01. (d) In VITVO live and dead staining after nivolumab treatment (48 hours) to visualize live (green) and dead (red) cells. Representative images of untreated sample (left pic) and treated sample (right pic) are shown. Scale bar 1,000 μm.

Back to article page